Increasing Prostate Specific Antigen Following Radical Prostatectomy and Adjuvant Hormonal Therapy: Doubling Time Predicts Survival

Journal of Urology

Volumn 175, Issue 5, 2006, Pages 1684-1690

  Sengupta, Shomik ^a   Blute, Michael L ^a   Bagniewski, Stephanie M ^a   Myers, Robert P ^a   Bergstralh, Eric J ^a   Leibovich, Bradley C ^a   Zincke, Horst ^a  

^a Department of Health Sciences Research ^*  (United States)

Author keywords

mortality; prostate; prostate specific antigen; prostatectomy; prostatic neoplasms

Indexed keywords

ANTIANDROGEN; GONADORELIN DERIVATIVE; PROSTATE SPECIFIC ANTIGEN;

ARTICLE; CALCULATION; CANCER GRADING; CANCER GROWTH; CANCER HORMONE THERAPY; CANCER MORTALITY; CANCER SURGERY; CANCER SURVIVAL; CONFIDENCE INTERVAL; CONTROLLED STUDY; FOLLOW UP; GLEASON SCORE; HUMAN; KAPLAN MEIER METHOD; LINEAR REGRESSION ANALYSIS; LOGLINEAR MODEL; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; POSTOPERATIVE PERIOD; PREDICTION; PREDICTOR VARIABLE; PREOPERATIVE PERIOD; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; PROSTATE CANCER; PROSTATECTOMY; SCORING SYSTEM; SEMINAL VESICLE; STATISTICAL SIGNIFICANCE;

ANDROGEN ANTAGONISTS; GONADOTROPIN-RELEASING HORMONE; HUMANS; MALE; NEOPLASM RECURRENCE, LOCAL; ORCHIECTOMY; PREDICTIVE VALUE OF TESTS; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; SURVIVAL RATE; TIME FACTORS;

EID: 33645964608     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-5347(05)00978-X     Document Type: Article

References (20)

1. Wirth M.P., See W.A., McLeod D.G., Iversen P., Morris T., and Carroll K. Bicalutamide 150 mg in addition to standard care in patients with localized or locally advanced prostate cancer. results from the second analysis of the early prostate cancer program at median followup of 5.4 years. J Urol 172 (2004) 1865
2. Zincke H., Lau W., Bergstralh E., and Blute M.L. Role of early adjuvant hormonal therapy after radical prostatectomy for prostate cancer. J Urol 166 (2001) 2208
3. Messing E.M., Manola J., Sarosdy M., Wilding G., Crawford E.D., and Trump D. Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. N Engl J Med 341 (1999) 1781
4. Cheng L., Zincke H., Blute M.L., Bergstralh E.J., Scherer B., and Bostwick D.G. Risk of prostate carcinoma death in patients with lymph node metastasis. Cancer 91 (2001) 66
5. Roberts S.G., Blute M.L., Bergstralh E.J., Slezak J.M., and Zincke H. PSA doubling time as a predictor of clinical progression after biochemical failure following radical prostatectomy for prostate cancer. Mayo Clin Proc 76 (2001) 576
6. Pound C.R., Partin A.W., Eisenberger M.A., Chan D.W., Pearson J.D., and Walsh P.C. Natural history of progression after PSA elevation following radical prostatectomy. JAMA 281 (1999) 1591
7. Moul J.W., Wu H., Sun L., McLeod D.G., Amling C., Donahue T., et al. Early versus delayed hormonal therapy for prostate specific antigen only recurrence of prostate cancer after radical prostatectomy. J Urol 171 (2004) 1141
8. Cheng W.S., Bergstralh E.J., Frydenberg M., and Zincke H. Prostate-specific antigen levels after radical prostatectomy and immediate adjuvant hormonal treatment for stage D1 prostate cancer are predictive of early disease outcome. Eur Urol 25 (1994) 189
9. Leo M.E., Bilhartz D.L., Bergstralh E.J., and Oesterling J.E. Prostate specific antigen in hormonally treated stage D2 prostate cancer. is it always an accurate indicator of disease status?. J Urol 145 (1991) 802
10. Petrylak D.P., Tangen C.M., Hussain M.H., Lara Jr. P.N., Jones J.A., Taplin M.E., et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 351 (2004) 1513
11. Tannock I.F., de Wit R., Berry W.R., Horti J., Pluzanska A., Chi K.N., et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351 (2004) 1502
12. Nativ O., Winkler H.Z., Raz Y., Therneau T.M., Farrow G.M., Myers R.P., et al. Stage C prostatic adenocarcinoma. flow cytometric nuclear DNA ploidy analysis. Mayo Clin Proc 64 (1989) 911
13. Ward J.F., Slezak J.M., Blute M.L., Bergstralh E.J., and Zincke H. Radical prostatectomy for clinically advanced (cT3) prostate cancer since the advent of prostate-specific antigen testing. 15-year outcome. BJU Int 95 (2005) 751
14. van den Ouden D., Tribukait B., Blom J.H., Fossa S.D., Kurth K.H., ten Kate F.J., et al., European Organization for Research and Treatment of Cancer Genitourinary Group. Deoxyribonucleic acid ploidy of core biopsies and metastatic lymph nodes of prostate cancer patients. impact on time to progression. J Urol 150 (1993) 400
15. Davidson P.J., Hop W., Kurth K.H., Fossa S.D., Waehre H., Schroder F.H., and European Organization for Research and Treatment of Cancer Genitourinary Group. Progression in untreated carcinoma of the prostate metastatic to regional lymph nodes (stage T0 to 4, N1 to 3.M0, D1). J Urol 154 (1995) 2118
16. Cadeddu J.A., Partin A.W., Epstein J.I., and Walsh P.C. Stage D1 (T1-3, N1-3, M0) prostate cancer. a case-controlled comparison of conservative treatment versus radical prostatectomy. Urology 50 (1997) 251
17. Ghavamian R., Bergstralh E.J., Blute M.L., Slezak J., and Zincke H. Radical retropubic prostatectomy plus orchiectomy versus orchiectomy alone for pTxN+ prostate cancer. a matched comparison. J Urol 161 (1999) 1223
18. Partin A.W., Pearson J.D., Landis P.K., Carter H.B., Pound C.R., Clemens J.Q., et al. Evaluation of serum prostate-specific antigen velocity after radical prostatectomy to distinguish local recurrence from distant metastases. Urology 43 (1994) 649
19. Ward J.F., Zincke H., Bergstralh E.J., Slezak J.M., and Blute M.L. Prostate specific antigen doubling time subsequent to radical prostatectomy as a prognosticator of outcome following salvage radiotherapy. J Urol 172 (2004) 2244
20. D'Amico A.V., Moul J., Carroll P.R., Sun L., Lubeck D., and Chen M.H. Surrogate end point for prostate cancer specific mortality in patients with nonmetastatic hormone refractory prostate cancer. J Urol 173 (2005) 1572